title: Long-term follow-up of homoharringtonine plus all-trans retinoic acid-based induction and consolidation therapy in newly diagnosed acute promyelocytic leukemia.
abstract: We conducted a retrospective study to evaluate the efficacy of combining homoharringtonine (HHT) with all-trans-retinoic acid (ATRA)-based induction therapy, followed by three courses of consolidation chemotherapy and 2-year sequential maintenance therapy in acute promyelocytic leukemia (APL). Fifty-three patients were enrolled in the study. The complete remission (CR) rate was 100 %. No patient died during induction therapy. The 9-year event-free survival (EFS) and 9-year overall survival (OS) for all patients were 79.0 and 83.0 %, respectively. Outcome estimates according to the body mass index (BMI) were carried out. Twenty-three (43.4 %) were underweight/normal (BMI < 23.0 kg/m(2)), whereas 30 patients (56.6 %) were overweight/obese (BMI ≥ 23.0 kg/m(2)). Underweight/normal-weight patients had a 9-year OS of 100 %, compared with 73.0 % for overweight/obese patients (P = 0.044). These results indicate that HHT plus ATRA-based induction and consolidation therapy may be a highly efficacious treatment option for newly diagnosed APL. Increased BMI had an adverse prognostic impact in APL.
authors.affiliation: Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, No. 288, Nanjing Road, Tianjin, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Wang
authors.forename: Dong
authors.initials: D
authors.lastname: Lin
authors.forename: Hui
authors.initials: H
authors.lastname: Wei
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.forename: Bingcheng
authors.initials: B
authors.lastname: Liu
authors.forename: Chunlin
authors.initials: C
authors.lastname: Zhou
authors.forename: Kaiqi
authors.initials: K
authors.lastname: Liu
authors.forename: Yingchang
authors.initials: Y
authors.lastname: Mi
authors.forename: Jianxiang
authors.initials: J
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use* / Q000633:toxicity; D015992:Body Mass Index; D060830:Consolidation Chemotherapy; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006248:Harringtonines / Q000009:adverse effects / Q000627:therapeutic use* / Q000633:toxicity; D000077863:Homoharringtonine; D006801:Humans; D060828:Induction Chemotherapy; D015473:Leukemia, Promyelocytic, Acute / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014212:Tretinoin / Q000009:adverse effects / Q000627:therapeutic use* / Q000633:toxicity; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D006248:Harringtonines; D014212:Tretinoin; D000077863:Homoharringtonine